Provided by Tiger Fintech (Singapore) Pte. Ltd.

EyePoint

6.19
-0.0200-0.32%
Post-market: 6.450.2600+4.20%17:00 EDT
Volume:986.33K
Turnover:6.05M
Market Cap:425.43M
PE:-2.66
High:6.31
Open:6.18
Low:6.00
Close:6.21
Loading ...

EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.d., Fasrs to Board of Directors

THOMSON REUTERS
·
08 Jan

Press Release: EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D., FASRS to Board of Directors

Dow Jones
·
08 Jan

Citigroup Initiates EyePoint Pharmaceuticals at Buy With $33 Price Target

MT Newswires Live
·
07 Jan

Positive Outlook for EyePoint Pharmaceuticals Driven by Promising Prospects in the DME Market

TIPRANKS
·
03 Jan

EyePoint reports inducement grants under NASDAQ listing rule

TipRanks
·
17 Dec 2024

BRIEF-Eyepoint Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule

Reuters
·
16 Dec 2024

EyePoint Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
16 Dec 2024

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
16 Dec 2024

EyePoint Pharmaceuticals Price Target Maintained With a $22.00/Share by HC Wainwright & Co.

Dow Jones
·
05 Dec 2024

EyePoint doses first patient in second Phase 3 LUCIA clinical trial

TIPRANKS
·
04 Dec 2024

EyePoint Announces First Patient Dosed in Second Global Phase 3 Lucia Clinical Trial of Duravyu™ for the Treatment of Wet Age-Related Macular Degeneration

THOMSON REUTERS
·
04 Dec 2024

EyePoint Pharmaceuticals Inc - Topline Data for Phase 3 Pivotal Program Expected in 2026

THOMSON REUTERS
·
04 Dec 2024

EyePoint Announces First Patient Dosed in Second Global Phase 3 LUCIA Clinical Trial of DURAVYU™ for the Treatment of Wet Age-Related Macular Degeneration

GlobeNewswire
·
04 Dec 2024

EyePoint Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
18 Nov 2024

Press Release: EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Dow Jones
·
18 Nov 2024

EyePoint price target lowered to $33 from $38 at Baird

TipRanks
·
12 Nov 2024